OnKure to Present at the Stifel 2024 Healthcare Conference
OnKure Therapeutics (NASDAQ: OKUR), a clinical-stage biopharmaceutical company specializing in precision oncology medicines, has announced its participation in the Stifel 2024 Healthcare Conference. Nicholas Saccomano, Ph.D., President and CEO, will deliver a corporate presentation on November 18, 2024, at 1:50 p.m. ET in New York.
The presentation will be accessible via live webcast through the 'Events' section of OnKure's website, with a replay available for approximately 90 days following the event.
OnKure Therapeutics (NASDAQ: OKUR), un'azienda biofarmaceutica in fase clinica specializzata in medicinali di oncologia di precisione, ha annunciato la sua partecipazione alla Stifel 2024 Healthcare Conference. Nicholas Saccomano, Ph.D., Presidente e CEO, presenterà un intervento aziendale il 18 novembre 2024, alle 13:50 ET a New York.
La presentazione sarà accessibile tramite webcast dal vivo attraverso la sezione 'Eventi' del sito web di OnKure, con una replica disponibile per circa 90 giorni dopo l'evento.
OnKure Therapeutics (NASDAQ: OKUR), una empresa biofarmacéutica en etapa clínica especializada en medicamentos de oncología de precisión, ha anunciado su participación en la Stifel 2024 Healthcare Conference. Nicholas Saccomano, Ph.D., Presidente y CEO, realizará una presentación corporativa el 18 de noviembre de 2024, a la 1:50 p.m. ET en Nueva York.
La presentación estará disponible a través de una transmisión en vivo por webcast en la sección 'Eventos' del sitio web de OnKure, con una repetición disponible durante aproximadamente 90 días después del evento.
OnKure Therapeutics (NASDAQ: OKUR), 정밀 종양학 의약품을 전문으로 하는 임상 단계의 생명공학 회사가 Stifel 2024 Healthcare Conference에 참여한다고 발표했습니다. Nicholas Saccomano, Ph.D., 사장 겸 CEO가 2024년 11월 18일, 오후 1시 50분 ET에 뉴욕에서 기업 발표를 할 예정입니다.
발표는 OnKure 웹사이트의 '이벤트' 섹션을 통해 실시간 웹캐스트로 접근할 수 있으며, 이벤트 이후 약 90일간 다시 볼 수 있는 재생이 제공됩니다.
OnKure Therapeutics (NASDAQ: OKUR), une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments d'oncologie de précision, a annoncé sa participation à la Stifel 2024 Healthcare Conference. Nicholas Saccomano, Ph.D., Président et CEO, fera une présentation d'entreprise le 18 novembre 2024 à 13h50 HE à New York.
La présentation sera accessible via un webinaire en direct dans la section 'Événements' du site Web d'OnKure, avec un replay disponible pendant environ 90 jours après l'événement.
OnKure Therapeutics (NASDAQ: OKUR), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Präzisionsonkologie-Medikamente spezialisiert hat, hat seine Teilnahme an der Stifel 2024 Healthcare Conference bekannt gegeben. Nicholas Saccomano, Ph.D., Präsident und CEO, wird am 18. November 2024 um 13:50 Uhr ET in New York eine Unternehmenspräsentation halten.
Die Präsentation wird über einen Live-Webcast im Bereich 'Veranstaltungen' auf der Website von OnKure zugänglich sein, mit einer Wiederholung, die etwa 90 Tage nach der Veranstaltung verfügbar sein wird.
- None.
- None.
BOULDER, Colo., Nov. 05, 2024 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (NASDAQ: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines in oncology, today announced that Nicholas Saccomano, Ph.D., President and Chief Executive Officer of OnKure Therapeutics, will present a corporate overview at the Stifel Healthcare Conference, on November 18, 2024 at 1:50 p.m. ET in New York, NY.
Stifel Healthcare Conference | |||
Date: | Monday, November 18, 2024 | ||
Time: | 1:50 p.m. ET | ||
Format: | Corporate Presentation | ||
Webcast: | Link | ||
A live webcast of the event can be accessed under “Events” on the Investor's section of the Company’s website at www.onkure.com. A replay of the corporate presentation will be available on the Company’s website for approximately 90 days.
About OnKure
OnKure is a clinical-stage biopharmaceutical company focused on the discovery and development of best-in-class precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using structure-based drug design platform, OnKure is building a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability. OnKure is currently developing OKI-219, a selective PI3KαH1047R inhibitor, as its lead program. OnKure aims to become a leader in targeting oncogenic PI3Kα and has multiple programs designed to enable best-in-class targeting of this key oncogene.
For more information about OnKure, visit us at www.onkure.com and follow us on LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. Such forward-looking statements include, among other things, statements regarding the potential of, and expectations regarding, OnKure’s product candidates and programs, including OKI-219; OnKure’s ability to advance additional programs; the expected milestones and timing of such milestones, including for OKI-219 and its discovery programs; and statements regarding OnKure’s financial position, including its liquidity, cash runway and the sufficiency of its cash resources. In some cases, you can identify forward-looking statements by terminology such as “estimate,” “intend,” “may,” “plan,” “potentially” “will” or the negative of these terms or other similar expressions.
The company based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, among other things, those risks described in the section entitled “Risk Factors” in documents that OnKure files from time to time with the Securities and Exchange Commission (“SEC”), including the final 424B3 proxy statement/prospectus filed with the SEC on August 26, 2024. These risks are not exhaustive. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by law, we undertake no obligation to update publicly any forward-looking statements for any reason after the date of this press release.
Contact:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
FAQ
When is OnKure Therapeutics (OKUR) presenting at the Stifel 2024 Healthcare Conference?
How can I watch OnKure's (OKUR) presentation at the Stifel 2024 Healthcare Conference?